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Objectives The purpose of this study was to assess the potential of late positive functional remodeling after percutaneous
pulmonary valve implantation (PPVI) in right ventricular outflow tract dysfunction.
Background PPVI has been shown to impact acutely on biventricular function and exercise performance, but the potential for
further late functional remodeling remains unknown.
Methods Sixty-five patients with sustained hemodynamic effects of PPVI at 1 year were included. Patients were divided
into 2 subgroups based on pre-procedural predominant pulmonary stenosis (PS) (n 35) or predominant pulmonary
regurgitation (PR) (n  30). Data from magnetic resonance imaging and cardiopulmonary exercise testing were
compared at 3 time points: before PPVI, within 1 month (early) and at 12 months (late) after PPVI.
Results There was a significant decrease in right ventricle end-diastolic volume early after PPVI in both subgroups of pa-
tients. Right ventricle ejection fraction improved early only in the PS group (51  11% vs. 58  11% and 51 
12% vs. 50  11%, p  0.001 for PS, p  0.13 for PR). Late after intervention, there were no further changes
in magnetic resonance parameters in either group (right ventricle ejection fraction, 58  11% in the PS group
and 52  11% in the PR group, p  1.00 and p  0.13, respectively). In the PS group at cardiopulmonary exer-
cise testing, there was a significant improvement in peak oxygen uptake early (24  8 ml/kg/min vs. 27  9
ml/kg/min, p  0.008), with no further significant change late (27  9 ml/kg/min, p  1.00). In the PR group,
no significant changes in peak oxygen uptake from early to late could be demonstrated (25  8 ml/kg/min vs.
25  8 ml/kg/min vs. 26  9 ml/kg/min, p  0.48).
Conclusions In patients with a sustained hemodynamic result 1 year after PPVI, a prolonged phase of maintained cardiac
function is observed. However, there is no evidence for further positive functional remodeling beyond the acute
effects of PPVI. (J Am Coll Cardiol 2011;57:724–31) © 2011 by the American College of Cardiology
Foundation
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predominant right ventricular outflow tract (RVOT) ob-
struction compared with those with significant pulmonary
regurgitation (PR). After reduction of RV afterload, pa-
tients showed an immediate improvement in right ventricle
From the *Cardiovascular Unit, University College London Institute of Child Health,
London, United Kingdom; †Cardiorespiratory Unit, Great Ormond Street Hospital
for Children, London, United Kingdom; ‡Department of Internal Medicine/
Cardiology and Grown Up Congenital Heart Disease, University of Leipzig-Heart
Center, Leipzig, Germany; §Department of Congenital Heart Disease and Pediatric
Cardiology, German Heart Institute Berlin, Berlin, Germany; Hopital Cardi-
ologique du Haut Leveque, Pessac, France; and the ¶Grown Up Congenital(RV) function and maximal exercise capacity (1–3); how-
ever, this is not seen in patients after restoration of PR (3,4).
Data on late physiological outcome after percutaneous
restoration of RVOT function are scarce. It is unknown
whether percutaneous restoration of RVOT function can
promote cardiac remodeling beyond the early period after
Heart Unit, The Heart Hospital NHS Trust, London, United Kingdom. Dr. Bonhoeffer
is a consultant to Medtronic and NuMed and has received honoraria and royalties for the
device described. Dr. Taylor has received speaker honoraria for Medtronic and has a
research agreement with Siemens. All other authors have reported that they have no
relationships to disclose. Drs. Lurz and Nordmeyer contributed equally to this work.Manuscript received March 25, 2010; revised manuscript received June 16, 2010,
accepted July 17, 2010.
725JACC Vol. 57, No. 6, 2011 Lurz et al.
February 8, 2011:724–31 Functional Outcome Post-PPVIintervention, thus improving cardiac function and exercise
capacity in the midterm, or whether it simply interrupts the
downward spiral of worsening cardiac function, leading to a
stabilization of biventricular performance and exercise
tolerance.
The aim of this study was to analyze the immediate and
1-year physiological responses to PPVI. In particular, we
sought to analyze whether further changes in biventricular
function and exercise performance (functional remodeling)
occurred after the immediate post-interventional period.
For this purpose, we enrolled patients into a prospective
study protocol that included magnetic resonance (MR)
imaging and cardiopulmonary exercise (CPEX) testing. To
avoid a significant confounding effect of restenosis or
occurrence of PR, only patients with a sustained hemody-
namic result 1 year after PPVI were included in this study.
Methods
Patients and study protocol. To assess the acute and late
effects of PPVI on biventricular function and exercise
performance, MR imaging and CPEX testing were per-
formed at 3 time points: first, within 1 month before PPVI
(before PPVI); second, within 1 month after PPVI (early
after PPVI); and third, 12 months after PPVI (late after
PPVI).
Patients underwent PPVI according to the clinical and
morphological criteria that have been published previously
(5–7) and were enrolled in this study from May 2004
through June 2008. For initial inclusion into the study,
patients had to fulfill the following criteria: no contraindi-
cations to MR imaging or CPEX testing, adequate MR
image quality for assessment of ventricular volumes and
great vessel blood flow, and symptom-limited maximal
CPEX results with a respiratory exchange ratio 1.09. To
avoid confounding of the data related to nonsustained
efficacy of the procedure, patients had to show a sustained
hemodynamic result 1 year after PPVI as assessed by
echocardiography (no increase in peak RVOT gradient15
mm Hg and no increase in PR). Only patients with a
complete MR imaging and CPEX testing data set at all 3
assessment stages were analyzed. In total, 65 of 107
screened patients met these inclusion criteria. Figure 1
summarizes reasons for exclusion from the study.
Patients were divided into 2 groups according to PR
fraction measured on MR imaging to separate patients
with predominant pulmonary stenosis (PR fraction
25%, n  35) from those with predominant PR (PR
fraction 25%, n  30). The New York Heart Association
(NYHA) functional class was assessed at the same clinical
contacts in all patients.
Written informed consent was obtained from patients
and parents as appropriate. The ethics committees at the 2
contributing institutions approved the study protocol (Great
Ormond Street Hospital for Children and The Heart
Hospital, London, United Kingdom).PPVI. The protocol for valve
implantation (Melody, Med-
tronic, Inc., Minneapolis, Min-
nesota) has been reported before
(5,8–10) and is summarized here
briefly for convenience. All im-
plants were performed under
general anesthesia. Vascular ac-
cess was achieved through the
femoral vein and artery. Standard
right heart catheterization, in-
cluding pressure measurements
and RVOT angiography, was
undertaken. Invasive systemic
pressures were monitored. Aortic
root angiography was performed
routinely to assess the proximity
of the coronary arteries to the
RVOT to avoid possible coro-
nary compression resulting from
PPVI. Simultaneous balloon in-
flation in the RVOT and coronary angiography was per-
formed in patients at risk for coronary obstruction (5,11–
13). Very stenotic, tortuous conduits were pre-dilated with
high-pressure Mullins balloons (NuMed, Hopkinton, New
York) or pre-stented with IntraStent Max LD stents (ev3
Intravascular, Plymouth, Minnesota). After PPVI, pressure
measurements and RVOT angiography were performed.
Post-dilatation with high-pressure Mullins balloons was
performed after PPVI where appropriate.
Echocardiography. All transthoracic echocardiographic
studies were performed on a Vivid 7 GE machine (Ving-
med, Milwaukee, Wisconsin). As an estimate of RV systolic
pressure, the RV-to-right atrium pressure gradient was
calculated from the tricuspid regurgitant jet (without addi-
tion of right atrial pressure). The peak RVOT gradient was
calculated from the continuous-wave Doppler velocity
across the RVOT (14). PR was defined qualitatively by
color flow Doppler (15).
CPEX testing. CPEX testing was performed on a bicycle
ergometer. The work rate increased with a ramp protocol of
10 to 20 W/min to reach exhaustion after approximately 10
min of exercise. Tests were considered to be maximal when
they were interrupted because of symptoms like fatigue or
dyspnea and a respiratory exchange ratio 1.09 was
achieved. A 12-lead electrocardiography test was monitored
continuously and blood pressures were recorded every 2 min
during CPEX testing. Breath-by-breath respiratory gas
exchange measurements were recorded throughout the test.
Peak oxygen uptake was defined as the average of the values
obtained in the last 20 s of exercise. Anaerobic threshold
was determined by the modified V-slope method (16).
Ventilatory efficiency, defined as the slope between minute
ventilation and carbon dioxide elimination (ventilatory ef-
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throughout the exercise period (17).
MR imaging. MR imaging was performed at 1.5-T (Sym-
phony Maestro Series and Avanto, Siemens Medical Solu-
tions, Erlangen, Germany). Retrospective gated steady-state
free-precession cine MR images of the heart were acquired
in the vertical long-axis view, 4-chamber view, short-axis
views that included the entirety of both ventricles (9 to 12
slices), and 2 long-axis planes of the RVOT and left
ventricular outflow tract for positioning of through-plane
flow quantification. Assessment of RV and left ventricular
volumes was performed by manually defining the endocar-
dial outline at end-diastole and end-systole in each of the
short-axis cine images (Argus, Siemens Medical Systems,
Erlangen, Germany). The end-diastolic volume (EDV) and
end-systolic volume (ESV) were calculated with Simpson’s
rule for each ventricle, and from these volumes, the stroke
Figure 1 Summary of Study Enrollment
and Reasons for Exclusion
Initial inclusion criteria (no contraindication to magnetic resonance [MR] imag-
ing and cardiopulmonary exercise [CPEX] testing; adequate MR and CPX data
before percutaneous pulmonary valve implantation [PPVI]) were met by 107
patients after intervention; 3 patients did not undergo assessment early after
PPVI because of procedural complications and rescue open-heart surgery. Of
the 104 patients undergoing assessment early after PPVI, 4 were excluded
because of inadequate MR data (n  2) and submaximal CPEX testing (n  2).
During follow-up, 30 patients were excluded from the study because of: second
valve-in-valve PPVI for early restenosis (n  2), sudden death presumably
resulting from arrhythmia (n  1), device explantation resulting from endocardi-
tis (n  1) and mechanical aortic valve failure (n  1); relevant restenosis as
defined by an increase in right ventricular outflow tract (RVOT) gradient 15
mm Hg as assessed on echocardiography (n  8); and missed assessment
late after PPVI in overseas patients (n  12). Finally, of 70 patients who under-
went assessment late after PPVI, 5 were excluded because of inadequate MR
data (n  2) and submaximal CPEX testing (n  3), leaving 65 patients for
final analysis.volume and ejection fraction (EF) were derived. The cine psteady-state free-precession sequence parameters were as
follows: repetition time, 2.4 ms; echo time, 1.1 ms; flip
angle, 60°; slice thickness, 8 to 10 mm (no gap in short-axis
stack); matrix size, 192  156; and field of view, 280 to 380
mm, with a temporal resolution of approximately 40 ms
reconstructed to 25 phases per cardiac cycle.
Aortic and pulmonary artery flow data were acquired with
a flow-sensitive gradient echo sequence during free breath-
ing. The detailed imaging protocols for assessment of
biventricular function and great vessel blood flow were
described previously (1). The flow sensitive gradient echo
sequence parameters were as follows: repetition time, 8 ms;
echo time, 3.8 ms; flip angle 30°; slice thickness, 5 mm;
matrix size 256  192; and field of view, 280 to 380 mm,
with a temporal resolution of approximately 30 ms recon-
structed to 30 phases per cardiac cycle.
Regurgitant fraction was calculated as the percent of
backward flow over forward flow. Where PR was present, an
effective RV stroke volume was calculated to reflect the net
forward blood flow into the pulmonary arteries as follows:
effective RV stroke volume  total pulmonary artery for-
ward flow  pulmonary artery backward flow. Tricuspid
regurgitation fraction was calculated as follows: total RV
stroke volume  total pulmonary artery forward flow. All
volume and flow measurements were indexed for body
surface area and expressed in milliliters per square meter.
Statistical analysis. Data are expressed as mean  SD.
Proportions are expressed as percentages. Two-paired sam-
ples were analyzed with a 2-tailed paired Student t test.
Parameters before PPVI were compared between the 2
groups with the unpaired Student t test or Mann-Whitney
U test. Categorical variables were compared using the Fisher
exact test. MR imaging, CPEX testing, and echocardio-
graphic data were compared with repeated-measures anal-
ysis of variance and post-hoc testing with Bonferroni
correction between the states early after PPVI and late after
PPVI. For comparison of NYHA functional class, a Fried-
man test was applied for comparison between the 3 points in
time within the same subgroups. All statistical testing was
based on a 2-sided   0.05 significance level. Statistical
esting and data analysis was performed with SPSS software
ersion 11 (SPSS, Inc., Chicago, Illinois) and GraphPad
rism software version 5.0b (GraphPad Software, San
iego, California).
esults
atient characteristics are shown in Table 1. The median
ge at the time of PPVI was 20.4 years (range 5.2 to 57.7
ears), and 38.5% of the patients were female. Most patients
63.1%) had tetralogy of Fallot or variant morphology.
ifty-nine of 65 patients (90.7%) had an RV-to-PA conduit
n situ, 5 patients had a native or patch-extended RVOT at
resentation, and 1 patient had a bioprosthetic valve in
ulmonary position. Baseline characteristics, including age,
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significantly between the PS and the PR groups.
Acute hemodynamic outcome. Invasive pressure measure-
ments are summarized in Table 2. PPVI resulted in a
significant reduction in RV systolic pressure, pulmonary
artery-to-RV pullback gradient, and RV end-diastolic pres-
sure in both groups. Further, PPVI led to an increase in
systemic systolic pressure in the PS group (93  15 mm Hg
vs. 102  14 mm Hg, p  0.004) and PR group (89  13
m Hg vs. 103  18 mm Hg, p  0.001).
chocardiography. Before PPVI, there were significantly
igher echocardiographic RVOT gradients in the PS group
ompared with the PR group (70  17 mm Hg vs. 41  18
m Hg, p 0.001). Early after PPVI, the RVOT gradients
ell significantly in the PS group (70  17 mm Hg vs. 35 
10 mm Hg, p  0.001, post-hoc testing before PPVI vs.
early after PPVI) and in the PR group (41  18 mm Hg vs.
27  11 mm Hg, p  0.001). Although this gradient
reduction remained unchanged at 1 year in the PR group
(27  11 mm Hg vs. 26  12 mm Hg; p  1.00, post-hoc
testing early after PPVI vs. late after PPVI), there was a
Baseline CharacteristicsTable 1 Baseline Characteristics
Parameter
Total Population
(n  65)
Age at implantation, yrs (range) 20.4 (5.2–57.7) 2
Female 25 (38.5)
Diagnosis
Tetralogy of Fallot variant 41 (63.1)
Double outlet right ventricle 3 (4.6)
TGA, VSD, PS 7 (10.8)
Ross procedure 5 (7.7)
Truncus arteriosus 6 (9.2)
Other 3 (4.6)
Open heart surgeries (mean) 2 (1–5)
Closed heart surgeries (mean) 0 (0–3)
Operations in total (mean) 2 (1–6)
NYHA functional class
I 10 (15.4)
II 39 (60.0)
III 15 (23.1)
IV 1 (1.5)
Values are n (%) unless otherwise specified.
NYHA  New York Heart Association; PR  pulmonary regurgitation; PS  pulmonary stenosis
Invasively Measured Hemodynamic Outcomes After Percutaneous PTable 2 Invasively Measured Hemodynamic Outcomes After Pe
Stenotic Group (n 
Before After
RV systolic pressure (mm Hg) 71 23 41 10
RV end-diastolic pressure (mm Hg) 13 5 10 4
RVOT gradient (mm Hg) 45 23 15 6
Aortic systolic pressure (mm Hg) 93 15 102 14
Aortic diastolic pressure (mm Hg) 57 11 61 9
RV-to-systemic pressure ratio (%) 0.74 0.16 0.40 0.08Values are mean  SD.
RV  right ventricle; RVOT  right ventricular outflow tract.further small reduction in RVOT gradient in the PS group
(35  10 mm Hg vs. 29  10 mm Hg, p  0.008).
MR imaging assessment and ventricular volumes and
function. Volumetric assessment of the RV and calculation
of pulmonary artery blood flow showed an improvement in
effective RV stroke volume early after PPVI in both the PS
and the PR group (Table 3). However, although RV EDV
and ESV decreased significantly early after PPVI in both
groups, RV EF improved only in the PS group with no
change in the PR group. PR fraction was reduced to a
minimum early after PPVI in both groups. There was a
significant increase in left ventricular EDV and effective
stroke volume in the PS and PR group early after
intervention.
On MR assessment late after PPVI, the initial improve-
ment in RV EF in the PS group was maintained with no
further change compared with early after PPVI (Fig. 2).
Also, there was no further reduction in RV EDV from early
to late after PPVI in this group. Volumetric assessment of
the LV in the PS group showed a slight, but significant,
increase in EDV and ESV late after PPVI with unchanged
Group
35)
PR Group
(n  30)
PS Group vs. PR Group
(p Value)
.0–44.1) 19.8 (5.2–57.7) 0.15
7.1) 12 (40.0) 1.00
0.0) 20 (66.7) 0.6
.9) 2 (6.7) 1.00
4.3) 2 (6.7) 0.44
.6) 2 (6.7) 1.00
.7) 4 (13.3) 0.40
.6) 0 0.24
–5) 1 (1–5) 0.08
–2) 0 (0–3) 0.40
–6) 2 (1–6) 0.37
9.0) 3 (10.0) 0.32
1.4) 21 (70.0) 0.20
5.7) 6 (20.0) 0.77
.9) 0 (0) 1.00
transposition of the great arteries; VSD  ventricular septal defect.
nary Valve Implantationneous Pulmonary Valve Implantation
Regurgitant Group (n  30)
p Value Before After p Value
0.001 51 16 39 10 0.001
0.001 11 4 9 3 0.02
0.001 22 12 12 7 0.001
0.004 89 13 103 18 0.001
0.17 54 11 61 11.6 0.009
0.001 0.57 0.19 0.37 0.09 0.001PS
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Functional Outcome Post-PPVI February 8, 2011:724–31LV EF compared with early after PPVI. In the PR group,
the MR findings were maintained with no significant
change in any MR parameters late after PPVI as compared
with early after PPVI (Fig. 2).
Before PPVI, there were no patients with severe tricuspid
regurgitation. The median tricuspid regurgitation fraction
was 0.0% (range 0% to 33%), with only 2 patients having a
tricuspid regurgitation fraction 20% (24% and 33%).
CPEX testing. The results of CPEX testing are shown in
Table 4. In the PS group, there was a significant improvement
in absolute measures of peak and percent of predicted peak
oxygen uptake, peak workload, oxygen uptake at anaerobic
threshold, and ventilatory efficiency slope early after PPVI.
This early improvement in cardiopulmonary exercise capacity
was maintained late after PPVI, with no further change in any
of these parameters compared with early after PPVI.
In the PR group, no improvement in peak oxygen uptake
and percent of predicted peak oxygen uptake, peak work-
load, oxygen uptake at anaerobic threshold, or ventilatory
efficiency slope could be demonstrated early after PPVI. On
repeated assessment of exercise capacity late after PPVI,
there was a significant increase in peak workload and
ventilatory efficiency slope as compared with parameters
before PPVI. No significant change in peak oxygen uptake,
percent of predicted peak oxygen uptake, and oxygen uptake
Magnetic Resonance Imaging Data Before, Early After, and LateAfter PPVI in the Pulmonary Stenosis and Pulmonary RegurgitatTable 3 Magnetic Reso ance Imagi g Data Be ore, Ea ly AftAfter PPVI in the Pulmonary Stenosis and Pulmonar
Parameter Before PPVI
Early Aft
PPVI
Predominantly stenotic (n  35)
RV EDV indexed (ml/m2) 97.4 30.4 86.9 2
RV ESV indexed (ml/m2) 50.9 26.3 40.6 2
RV SV indexed (ml/m2) 46.4 9.1 47.2 7
RV SV eff indexed (ml/m2) 38.8 7.9 45.1 7
RV EF (%) 50.7 10.7 57.7 1
PR fraction (%) 11.4 8.6 1.4 2
LV EDV indexed (ml/m2) 68.7 14.3 73.9 1
LV ESV indexed (ml/m2) 27.1 12.0 27.0 1
LV SV eff indexed (ml/m2) 39.9 7.7 46.1 6
LV EF (%) 62.3 9.6 64.6 8
Predominantly regurgitant (n  30)
RV EDV indexed (ml/m2) 118.2 32.3 101.1 3
RV ESV indexed (ml/m2) 60.5 31.0 53.9 2
RV SV indexed (ml/m2) 57.5 13.4 47.4 7
RV SV eff indexed (ml/m2) 34.9 7.3 44.3 6
RV EF (%) 50.9 11.9 49.5 1
PR fraction (%) 35.0 10.5 3.1 4
LV EDV indexed (ml/m2) 69.7 18.4 79.5 1
LV ESV indexed (ml/m2) 30.9 15.0 32.8 1
LV SV eff indexed (ml/m2) 37.2 7.2 45.4 6
LV EF (%) 56.9 10.7 60.1 9
ANOVA  analysis of variance; EDV  end-diastolic volume; EF  ejection fraction; eff  effec
SV  systolic volume; other abbreviation as in Table 1.at anaerobic threshold was seen late after PPVI. Peak heart crate and respiratory exchange ratio did not change early or
late after PPVI in either group.
Functional outcome (NYHA functional class). The func-
tional class fell from a median of NYHA II to NYHA I
early after PPVI (p 0.001, Friedman test), with no further
tatistically significant change late after PPVI (NYHA I).
or this categorical variable, 25% of patients were in NYHA
lass III or IV before PPVI, whereas 100% were in NYHA
lass I or II at 1 year. These improvements in functional
lass also were present when separate analyses for the PS or
he PR groups were made.
iscussion
n this study, we showed that the beneficial physiological
onsequences of PPVI seen in the acute setting (1–3) are
aintained at 1 year in those patients with preserved device
unction. However, although there was no worsening of
iventricular function or exercise capacity after 1 year, we have
o evidence that the process of RV remodeling and functional
mprovement extends beyond the 1-month period in this
atient group, as shown by MR imaging and CPEX results.
cute effects of relief of adverse RV loading conditions.
he present results confirm our previous findings that PPVI
n patients with predominant PS is associated with an early
ignificant improvement in RV systolic function and exer-
roupsnd Late
urgitation Groups
Late After
PPVI
p Value
(ANOVA)
Post-Hoc Analysis
Before
vs. Early
Early
vs. Late
85.9 20.3 0.001 0.001 1.00
38.2 17.5 0.001 0.001 0.90
47.8 7.7 0.70
45.7 8.0 0.001 0.001 1.00
57.8 10.5 0.001 0.001 1.00
1.9 3.5 0.001 0.001 1.00
77.5 14.2 0.001 0.002 0.04
30.1 12.1 0.008 1.00 0.03
46.2 7.5 0.001 0.001 1.00
62.3 9.0 0.02 0.0441 0.10
97.9 30.9 0.001 0.001 0.60
49.5 29.5 0.001 0.016 0.145
48.4 9.1 0.001 0.001 1.00
46.1 9.2 0.001 0.001 0.50
52.3 11.2 0.127
2.0 3.5 0.001 0.001 0.60
82.3 25.6 0.001 0.001 0.71
35.2 21.6 0.064
46.3 9.3 0.001 0.001 1.00
60.2 10.9 0.037 0.11 1.00
V  end-systolic volume; PPVI percutaneous pulmonary valve implantation; RV right ventricle;ion Ger, a
y Reg
er
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February 8, 2011:724–31 Functional Outcome Post-PPVIof reduced RV pressure loading during exercise. This
concurs with the experience of Jonsson et al. (18), who were
able to demonstrate an association between RV systolic
hypertension and reduced cardiac output response during
exercise in patients with repaired tetralogy of Fallot, as a
consequence of exercise-induced increases of RVOT pres-
sure gradients. Under these conditions, significant RVOT
obstruction limits the normal augmentation of cardiac
output, which is elicited by exercise, thus reducing exercise
Figure 2 Change in RV EF as Assessed on MR Imaging
Initially, percutaneous pulmonary valve implantation (PPVI) led to a significant
increase in right ventricular (RV) ejection fraction (EF) in the pulmonary steno-
sis (PS) group, whereas there was no significant change in the pulmonary
regurgitation (PR) group. On late assessment 1 year after PPVI, no further
changes in RV EF were seen, either in the PS group or in the PR group. *Signif-
icant change (p  0.05) from before PPVI to early after PPVI.
Cardiopulmonary Exercise Testing Data Before, Early After, and LaTable 4 Cardiopulmonary Exercise Testing Data Before, Early A
Parameter Before PPVI
Early Afte
PPVI
Predominantly stenotic (n  35)
% of predicted peak VO2 (%) 59.9 14.8 67.7 17
Peak VO2 (ml/kg/min) 23.8 7.9 26.8 8.
VO2 at AT (ml/kg) 14.5 4.6 16.3 5.
Peak work (Watts) 136.7 52.5 147.7 54
VE/VCO2 slope 34.8 8.2 30.0 6.
HR at peak exercise (beats/min) 166.8 25.9 163.8 24
RER at peak exercise 1.18 0.08 1.18 0.
Predominantly regurgitant (n  30)
% of predicted peak VO2 (%) 65.0 16.4 66.9 17
Peak VO2 (ml/kg/min) 24.8 7.7 25.4 7.
VO2 at AT (ml/kg) 13.8 5.9 14.1 5.
Peak work (Watts) 108.3 41.7 110.9 42
VE/VCO2 slope 32.6 6.1 31.1 5.
HR at peak exercise (beats/min) 164.6 22.4 161.3 22
RER at peak exercise 1.16 0.05 1.16 0.AT  anaerobic threshold; HR  heart rate; RER  respiratory exchange ratio; VE/VCO2  ventilatory efcapacity. Indeed, we recently were able to demonstrate that
reduction in RVOT gradient was the only independent
predictor of improved exercise capacity early after PPVI (4).
Conversely, in patients with predominant PR we ob-
served no improvement in exercise capacity early after
PPVI, despite a higher net flow to the pulmonary vascula-
ture (increased effective RV SV) measured at rest. We
postulate that the explanation for this finding is related to
the fact that PR seems to be reduced to a minimum (both
as percentage and as absolute value) at peak exercise and is
not the limiting factor for cardiac output augmentation
during exercise. This is likely to be related to shortening of
diastole and reduced pulmonary vascular resistance during
exercise (19). Therefore, by purely abolishing PR without
improving RV ejection fraction, peak oxygen uptake may
not be affected by PPVI acutely in this patient subgroup (4).
ate effects of relief of adverse RV loading conditions.
lthough acute functional changes after PPVI could be
ttributed to the load-dependent function of the RV (1,4,8)
nd to the consequences of ventricular interaction (2), a
urther remodeling of cardiac function and exercise capacity
ate after relief of adverse RV loading conditions could have
een expected as a result of cardiac remodeling. However,
lthough the early acute hemodynamic outcomes were well
aintained at 1 year, we found no clear evidence for
linically relevant structural or functional improvement
eyond the 1-month period in either subgroup.
On MR assessment in the PS group, there was no change
n RV parameters late after PPVI as compared with early
fter PPVI. There was a significant increase in left ventric-
lar EDV and ESV. We previously showed that the acute
ncrease in left ventricular EDV is related to optimized
entricular interaction and increased filling of the left
entricle (2). The increase in left ventricular EDV 1 year
er PPVI in the PS and PR Groupsand Late After PPVI in the PS and PR Groups
Late After
PPVI
p Value
(ANOVA)
Post-Hoc Analysis
Before
vs. Early
Early
vs. Late
68.9 17.3 0.001 0.008 1
27.2 8.8 0.001 0.008 1
16.4 5.6 0.042 0.04 1
155.0 57.1 0.013 0.23 0.61
29.9 5.7 0.001 0.001 1
164.0 20.9 0.52 1 1
1.2 0.1 0.99 1 1
69.8 19.8 0.036 0.41 0.52
26.1 8.5 0.057 0.69 0.48
14.2 6.2 0.43 1 1
123.7 43.8 0.002 0.77 0.009
29.5 5.0 0.001 0.24 0.051
162.3 19.8 0.58 1 1
1.16 0.06 0.6 1 1te Aftfter,
r
.3
9
7
.5
2
.0
08
.6
6
0
.0
7
.3
05ficiency; VO2  oxygen uptake; other abbreviations as in Tables 1 and 3.
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response to the acute improvement in filling over time;
however, this cannot be answered in this study.
In the PR group, we found a nonsignificant tendency
toward further reduction in RV EDV and improved RV EF
1 year after PPVI. Further studies have to clarify whether
these changes can be attributed to late RV remodeling.
Similar to the MR data, there was a tendency toward
improved peak oxygen uptake and ventilatory efficiency on
CPEX testing, but these subtle changes are unlikely to be of
clinical relevance. Further, we found a significant increase in
peak workload in the PR group. However, this finding is
difficult to interpret as a follow-up parameter in growing
children, because the studied parameter is not indexed for
body weight. Assessment of patients’ functional class re-
vealed a further but nonsignificant reduction in the total
number of patients in NYHA functional class II late after
PPVI. Importantly, these 1-year results after PPVI predom-
inantly for PR are in keeping with studies on surgical
pulmonary valve replacement for PR, in which no signifi-
cant improvement in peak oxygen uptake 1 year after
surgery could be demonstrated (20,21).
In our opinion, with the current technique and indica-
tions for PPVI, the acute changes after PPVI are main-
tained 1 year after the intervention. However, no further
relevant positive RV remodeling or functional improvement
is seen as compared with early after PPVI.
The following factors may have limited positive late
remodeling in the present study:
1. The hemodynamic result achieved by PPVI might not
have been sufficient to allow for positive remodeling.
Because only patients with sustained hemodynamic re-
sults were included in this study, the initial hemody-
namic improvement was well maintained in the PR
group with even further reduction in RVOT gradients in
the PS group over time. Although this certainly should
have limited the confounding effects of worsening RV
loading conditions over time, some degree of residual
RVOT obstruction was present in most patients. This
hemodynamic finding was present in the PS and also in
the PR group, where the impact of even low-pressure
gradients is unknown.
2. PPVI might have been performed too late. Previous
studies in the surgical literature that assessed functional
outcome after pulmonary valve replacement have sug-
gested that patients with severe PR often may be treated
too late (20,22). This conclusion is based on the lack of
improvement in RV function after pulmonary valve
replacement. Similarly, in our study we also did not
observe improvement in RV EF or exercise performance
in patients with predominant PR, either immediately
after PPVI or at 1 year. However, it remains unknown
whether earlier performance of PPVI in this subgroup of
patients would have resulted in improved outcomes.3. Patients might not have been followed up for long
enough. Adverse RV remodeling in these chronically ill
patients may be reversible only in the long term.
4. RVOT dysfunction and adverse RV loading conditions
represent only one of many possible contributors to
functional impairment in these patients. The deleterious
effects of neonatal hypoxia and cyanosis, high pulmonary
pressures, multiple cardiopulmonary bypasses with long
ischemic time and transient inflammation, and ventric-
ular scaring resulting from surgery—all seen in patients
with CHD involving the RVOT—could be affected only
mildly by improved RV loading conditions after PPVI.
Although certainly multifactorial, the contribution of
adverse RV loading on impaired functional outcome in
these patients may be less relevant than commonly
believed. Further studies have to clarify the role of
pulmonary valve replacement in patients with RVOT
dysfunction for long-term patient management and
outcome.
Study limitations. Although we saw no significant remod-
eling in our patients at 1 year, our study period may be too
short and remodeling may occur over longer periods of time.
The outcome parameters used in this study represent only
selected proxies. Hard end point, such as mortality or
arrhythmia burden, which are rare in studies on patients
with congenital heart disease for well-known reasons, are
still missing when procedural success of RVOT interven-
tions is assessed. Further, the true onset of RVOT dysfunc-
tion could not be determined for each individual patient;
thus, the data set does not allow for definite conclusions
about the timing of intervention. Finally, the relatively small
sample size represents a limitation of this study. Therefore,
the findings need to be confirmed in larger cohorts.
Conclusions
With the current technique and indications for PPVI,
patients can benefit from a prolonged phase of maintained
cardiac function; however, they cannot expect significant
further improvement in biventricular function and objective
exercise performance 1 year after intervention. These results
underline the need for further studies to address the ques-
tion of when to intervene and how to achieve optimal
hemodynamic acute and long-term results after RVOT
intervention. At present, we suggest an aggressive approach
to any acute post-procedural residual RVOT gradient.
Importantly, in patients with chronic volume overload, even
small gradients may have significant detrimental effects on
RV function.
In patients with predominant PS, despite the lack of further
remodeling at 1 year, the initial marked improvement is
encouraging. In contrast, we observed no improvement in RV
systolic function or exercise capacity in the PR group, which
may suggest that in patients with severe PR, interventions
should be considered before reduction in RV function or
deterioration in exercise performance are observed.
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